Francis Medical Completes Record $80 Million Series C Equity Financing
Francis Medical, a leader in innovative treatments for prostate cancer, has successfully closed a record $80 million Series C equity financing round. This significant funding will be instrumental in advancing the company’s mission to revolutionize the treatment of prostate cancer, particularly through its pioneering approach to thermal therapy. With this fresh infusion of capital, Francis Medical plans to accelerate the development of its proprietary technology, expand clinical trials, and prepare for the commercialization of its flagship product.
The Series C round was led by a group of prominent investors, including venture capital firms specializing in healthcare and biotechnology. The funding also saw participation from existing investors, who have continued to support the company’s growth and vision for transforming prostate cancer care. With this investment, Francis Medical is poised to make substantial progress in its mission of improving the lives of prostate cancer patients through safer, less invasive treatment options.
“We are thrilled to close this record-breaking Series C financing, which positions us to continue advancing our proprietary thermal therapy treatment for prostate cancer,” said Dr. Mark Francis, CEO and founder of Francis Medical. “Prostate cancer remains one of the most common cancers in men, and despite advancements in treatment, there is still a need for safer, more effective therapies. Our innovative approach has the potential to provide patients with an alternative to traditional treatments, and this funding allows us to take a significant step forward in bringing our technology to market.”
Founded in 2018, Francis Medical has focused on developing minimally invasive treatments that address the unmet needs of prostate cancer patients. The company’s flagship technology, the FocalTherm™ system, is an advanced thermal therapy platform designed to treat localized prostate cancer. Using heat to target and destroy cancer cells, the system aims to provide a less invasive, more targeted treatment compared to traditional methods such as surgery or radiation. This approach is designed to minimize side effects and recovery time while maintaining high efficacy in treating cancerous tissue.
Prostate cancer is the second most common cancer among men globally, with over 1.4 million new cases diagnosed each year. Despite significant progress in the field, many current treatments come with challenges, such as potential complications, long recovery times, and significant impact on the patient’s quality of life. FocalTherm™ aims to address these issues by offering a more precise and less invasive option that focuses directly on the cancerous tissue while minimizing damage to surrounding healthy tissue.
The $80 million raised in the Series C round will be used to accelerate the clinical development of the FocalTherm™ system. The funds will support ongoing clinical trials, including studies to demonstrate the safety and effectiveness of the technology in treating prostate cancer. Additionally, the company plans to expand its regulatory efforts to secure necessary approvals and prepare for commercial launch. The investment will also be directed towards enhancing the technology’s capabilities, including improving its precision, ease of use, and scalability for a wider range of patients.
“Francis Medical’s innovative approach to prostate cancer treatment offers significant promise for patients and the medical community,” said Sarah Thompson, Managing Director at MedTech Ventures, one of the lead investors in the Series C round. “We are excited to support the company as it continues to develop its cutting-edge technology and move closer to making a meaningful impact in prostate cancer care. The potential of FocalTherm™ to provide patients with a safe, effective, and minimally invasive treatment is groundbreaking, and we look forward to the company’s future success.”
The funding will also enable Francis Medical to strengthen its leadership team and expand its operations. The company plans to hire additional talent in areas such as clinical development, regulatory affairs, and commercial operations to ensure that it is well-positioned to bring FocalTherm™ to market and achieve widespread adoption.
In addition to its clinical and regulatory efforts, Francis Medical is also focused on educating healthcare providers and patients about the benefits of thermal therapy for prostate cancer. The company plans to collaborate with healthcare professionals and institutions to promote awareness of its technology and provide training on its use. By building strong relationships with the medical community, Francis Medical aims to ensure that its innovative treatment is accessible to those who need it most.
Looking ahead, Francis Medical is committed to continuing its work in developing novel, minimally invasive treatments for prostate cancer. The company’s approach aligns with the growing demand for personalized and precision medicine, offering patients more tailored treatment options that consider their unique medical needs. With its promising technology, strong leadership team, and now the backing of a successful Series C financing round, Francis Medical is on track to make a lasting impact in the field of prostate cancer care.
The $80 million raised in this financing round marks a critical milestone in Francis Medical’s journey. The company is now poised to take its innovative thermal therapy treatment to the next level, with the potential to change the way prostate cancer is treated and improve the quality of life for thousands of patients worldwide. With the support of its investors and the continued development of FocalTherm™, Francis Medical is set to revolutionize prostate cancer treatment, offering new hope to those affected by the disease.
